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 Abstract 
Background: This study examined if CF mutation heterozygosity is associated with diseases of gastrointestinal epithelial barrier function.
 
Design and methods: Swedish registers identified 865 patients with a diagnosis of CF between 1968 and 2003 and matched with 8101 individuals
 
without CF. Gastrointestinal disease risk was examined among 1534 biological parents and 1396 siblings of CF patients, compared with 15,526
 
parents and 15,542 siblings of individuals without CF.
 
Results: First-degree relatives of CF patients were not at lower risk of the gastrointestinal diseases, in contrast with a raised risk among CF
 
patients.
 
Conclusion: Heterozygosity for CF gene mutations does not protect against gastrointestinal diseases where impaired barrier function may be
 
relevant.
 
© 2010 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
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While there is little evidence that increased fertility [2] 
accounts for the relatively high frequency of CF gene mutations 
among Caucasians, [1] there may be some protection from 
gastrointestinal and other infections [3,4]. The  entry of
infectious agents into epithelial cells is impaired in animals 
heterozygous for CF polymorphisms [4]. Despite normal 
intestinal chloride secretion in humans [5], improved gastroin­
testinal barrier function may theoretically contribute to 
protection, including against diseases involving an immune 
response against luminal contents (such as bacteria) including 
peptic ulcer [6], coeliac disease, ulcerative colitis and Crohn's ⁎ Corresponding author. Clinical Epidemiology Unit, Department of Medi­
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doi:10.1016/j.jcf.2010.03.010 disease [7]. We examined the risk of these diseases in first-
degree relatives of CF patients as the majority would be 
heterozygous for CF mutations and compared them with 
relatives of a matched cohort without CF. To examine the 
specific role of likely barrier function, diseases where barrier 
function is less relevant were also investigated: pancreatic 
diseases, cholelithiasis, diverticulitis, appendectomy, cholecys­
titis, and fibrosis and cirrhosis of liver. The risks for the 
gastrointestinal diseases were also estimated among the CF 
patients. 
2. Subjects and methods 
The Swedish Inpatient Register [8] identified Swedish 
patients with a diagnosis of CF between 1968 and 2003 (ICD­
8 code 273.0; ICD-9 code 277.0; and ICD-10 code E84), age 60 
or less at follow-up as CF patients rarely live beyond 60 years of 
age [9]. The 865 patients were matched with 10 individuals d by Elsevier B.V. All rights reserved. 
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sex, vital status at diagnosis and region of residence (n =8101). 
The Multi-Generation Register [10] identified 759 and 7707 
biological fathers, 775 and 7819 biological mothers of subjects 
with and without CF, respectively. Failure to identify parents 
was mainly due to births before 1932, pre-dating inclusion in 
the register [10]. Some 1396 and 15,542 siblings of subjects 
were identified with and without CF, respectively. The Inpatient 
Register was used to identify diagnoses of gastrointestinal 
diseases. This study was approved by Karolinska Institutet 
regional ethics committee. 3. Statistical analysis 
Cox regression (SAS software) was used to estimate the risk 
of the gastrointestinal diseases. Parents and siblings of patients 
with a diagnosis of CF were compared with parents and siblings 
of the cohort without CF. We excluded 114 siblings who also 
had a CF diagnosis. Follow-up was from 1964, when the 
Inpatient Register was established, or from birth or immigration 
if this occurred subsequently; and continued until emigration, 
death, or 31st December 2003. The underlying time scale for all 
models was attained age, and adjustment was for the matching 
characteristics used to define risk-sets. The Cox regression was 
internally stratified by calendar period (in ten-year intervals). 4. Results 
The average follow-up time for parents of CF patients and 
the comparison parents was over 36.0 years. Siblings of patients 
with CF and comparison siblings were followed for an average 
of 23.0 years. The index subjects with and without CF were 
followed for averages of 21.0 and 23.5 years, respectively. Table 1 
Gastrointestinal disease risk among parents of patients with cystic fibrosis (759 fath
cystic fibrosis (7707 fathers and 7819 mothers). 
Mothers 
Events exposed/unexposed HR 9
Diseases of impaired barrier function 
Peptic ulcer 
Gastric ulcer 
Duodenal ulcer 
Ulcerative colitis 
Crohn's disease 
Coeliac disease 
10/93 
3/47 
4/35 
3/30 
2/28 
2/11 
1.03 
0.64 
1. 12
1.02 
0.75 
1.91 
Other diseases 
Acute pancreatitis 
Other diseases of pancreas 
Cholelithiasis 
Diverticulitis 
Appendectomy 
Only appendicitis 
Cholecystitis 
Fibrosis and cirrhosis of liver 
5/36 
2/7 
56/476 
12/89 
57/482 
17/242 
4/61 
2/17 
1.47 
3.07 
1.20 
1.33 
1.20 
0.70 
0.66 
1.18 
HR 95% CI — hazard ratio and 95% confidence interval. 4.1. First-degree relatives 
There was no notable risk reduction for any of the diseases 
among parents (Table 1) and siblings (Table 2) of patients with 
CF. In stratified analyses there was no increased or decreased 
risk of the gastrointestinal diseases among mothers of those with 
CF. The risks for gastric ulcer and ulcerative colitis were 
statistically significantly increased among fathers of patients 
with CF. There were no statistically significant associations in 
siblings (Table 2). Stratification by sex did not reveal notable 
associations. 
Stratification by calendar year of CF diagnosis, to tackle 
possible variation in diagnostic accuracy and differences in 
follow-up time, did not alter any of the results notably. 
4.2. Cystic fibrosis patients 
Among patients with CF, we observed statistically signifi­
cant increased risks for peptic ulcer, ulcerative colitis, Crohn's 
disease, coeliac disease, pancreatic diseases, cholelithiasis, 
appendectomy, cholecystitis, and fibrosis and cirrhosis of the 
liver, compared with individuals without CF (Table 3). 
5. Discussion 
Contrary to our hypothesis, there was no evidence of reduced 
risk for any of the diseases among first-degree relatives of CF 
patients and we identified statistically significant excess risks 
for gastric ulcer and ulcerative colitis among fathers. This was 
similar to our previous finding of no protective effect against 
cancer in relatives of CF patients [11]. As expected, the patients 
with CF in this study were at a higher risk of having a range of 
gastrointestinal diseases. 
The relative risks for some of the gastrointestinal diseases in 
relatives were close to unity, consistent with an earlier study of ers and 775 mothers) compared with parents of the comparison group without 
Fathers 
5% CI Events exposed/unexposed HR 95% CI 
(0.54–1.99) 
(0.20–2.07) 
 (0.40–3.17) 
(0.31–3.36) 
(0.18–3.14) 
(0.42–8.72) 
21/168 
15/57 
5/76 
8/33 
1/17 
0/4 
1.14 (0.72–1.80) 
2.39 (1.35–4.25) 
0.62 (0.25–1.54) 
2.48 (1.14–5.40) 
0.60 (0.08–4.54) 
– 
(0.57–3.74) 
(0.63–14.9) 
(0.91–1.58) 
(0.73–2.45) 
(0.91–1.58) 
(0.43–1.14) 
(0.24–1.83) 
(0.27–5.10) 
7/65 
4/18 
21/182 
8/73 
29/372 
23/242 
3/41 
3/47 
1.08 (0.49–2.35) 
2.11 (0.71–6.27) 
1.11 (0.71–1.75) 
1.07 (0.52–2.23) 
0.81 (0.55–1.18) 
0.98 (0.64–1.51) 
0.62 (0.19–2.02) 
0.64 (0.20–2.06) 
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Table 2 
Gastrointestinal disease risk among siblings of patients with cystic fibrosis 
(n =1396) compared with siblings of the comparison group without cystic 
fibrosis (n =15,542). 
Events exposed/unexposed HR, 95% CI 
Diseases of impaired barrier function 
Peptic ulcer 7/46	 1.48 (0.66–3.34) 
Only gastric ulcer 3/20	 1.49 (0.43–5.13) 
Only duodenal ulcer 4/20 1.97 (0.65–5.97) 
Ulcerative colitis 1/36 0.34 (0.05–2.53) 
Crohn's disease 4/29 1.51 (0.53–4.32) 
Coeliac disease 3/31 1.08 (0.33–3.53) 
Other diseases 
Acute pancreatitis 4/27 1.54 (0.53–4.44) 
Other diseases of pancreas 2/8 2.13 (0.43–10.55) 
Cholelithiasis 16/182 0.89 (0.53–1.49) 
Diverticulitis 3/30 1.04 (0.31–3.51) 
Appendectomy 69/768 0.99 (0.77–1.26) 
Only appendicitis 42/544 0.86 (0.63–1.17) 
Cholecystitis 3/23 1.16 (0.33–4.02) 
Fibrosis and cirrhosis of liver 1/14 1.03 (0.13–7.98) 
HR 95% CI — hazard ratio and 95% confidence interval. associations with cholelithiasis and liver cirrhosis in carriers of 
CF gene mutations [12]. However, we cannot rule out the 
possibility that a protective effect is masked by our use of a 
cohort of first-degree relatives of patients with a diagnosis of CF 
(rather than identifying heterozygosity through screening). It is 
possible that a proportion of such individuals are compound 
heterozygous for CF, and also carry a second mutation on the 
other chromosome resulting in a sub-clinical or variant form of Table 3
 
Gastrointestinal disease risk among patients with cystic fibrosis (n =865)
 
compared with the comparison group without cystic fibrosis (n =8101).
 
Events Events HR.95% CI 
among among 
subjects subjects 
with CF without CF 
Diseases of impaired barrier function 
Peptic ulcer 14 14 16.97 (7.83–36.81) 
Ulcerative 6 16 4.98 (1.92–12.88) 
colitis 
Crohn's 6 17 4.69 (1.83–12.03) 
disease 
Coeliac 30 15 21.21 (11.36–39.60) 
disease 
Other diseases 
Acute 12 9 23.50 (8.73–63.25) 
pancreatitis 
Other diseases 19 5 48.49 (17.81–132.06) 
of pancreas 
Cholelithiasis 28 83 5.57 (3.56–8.69) 
Diverticulitis 2 13 2.64 (0.57–12.17) 
Appendectomy 47 364 1.70 (1.25–2.30) 
Cholecystitis 10 8 20.41 (7.63–54.59) 
Fibrosis 42 10 62.14 (29.08–132.80) 
and cirrhosis 
of liver 
HR 95% CI — hazard ratio and 95% confidence interval. CF [13] themselves, thus increasing gastrointestinal disease risk 
as observed in patients with CF. The statistically significant 
risks for gastric ulcer and ulcerative colitis among fathers who 
were CF gene mutation carriers are not consistent with our 
hypothesis, and may represent a chance finding. 
Consistent with results from previous studies [13–15], the 
patients with CF were at a higher risk of Crohn's disease, celiac 
disease, pancreatic diseases, cholelithiasis, cholecystitis, and 
fibrosis and cirrhosis of liver. In contrast with earlier reports of 
lower risk of appendectomy among patients with CF [16,17] we 
observed a higher risk of appendectomy among CF patients. 
When we restricted the analysis to appendectomy due only to 
acute appendicitis (data not shown), the raised risk was no 
longer observed. The frequent examinations experienced by CF 
patients may have resulted in an over-estimation of associations 
with some diseases. 
This study had some potential limitations. Although we had 
information on all inpatients diagnosed with CF in Sweden over 
a long period, the number of patients with CF remained small. 
Although the DF508 mutation is the most common in CF, we 
did not have information on mutation-type and could not 
investigate specific associations. Diseases were identified using 
the Swedish Inpatient Register, the validity of which is 
generally high [18] and bias due to diagnostic misclassification, 
if any, is likely to move relative risks toward the null thus 
potentially masking any protective effect among first-degree 
relatives. 
In conclusion, we did not observe any significant risk 
reduction for the gastrointestinal diseases among people 
identified as likely heterozygous CF gene mutation carriers. 
Patients with CF are at higher risk of hospital admission for a 
variety of gastrointestinal diseases. Acknowledgment 
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